ArticleJournal for immunotherapy of cancer2020
Immunogenicity of cell death driven by immune effectors.
Article in Journal for immunotherapy of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Oncolytic virus-delivered GSDME: Unlocking pyroptosis to improve dendritic cell function and amplify cytotoxic T cell response.Molecular therapy. Oncology · 2026Article
- The E2F1-HMGCR axis promotes ferroptosis resistance in immune refractory tumor cells.Nature communications · 2025Article
- Simultaneous induction of immunogenic cell death and PD-L1 downregulation by bufalin-based nanovaccines for potentiate HCC immunotherapy.Materials today. Bio · 2025Article
- Inflammatory mitochondrial signalling and viral mimicry in cancer.Journal of translational medicine · 2025Review
- Utidelone suppresses PDAC growth and enhances gemcitabine therapy by inducing immunogenic cell death.iScience · 2025Article
- Photothermal Prussian blue nanoparticles generate potent multi-targeted tumor-specific T cells as an adoptive cell therapy.Bioengineering & translational medicine · 2024Article
- Shifting the paradigm: engaging multicellular networks for cancer therapy.Journal of translational medicine · 2024Review
- Synergistic Photothermal Tumor Immunotherapy by 1-MT Based on Zeolitic Imidazolate Framework-8 with pH-High Sensitivity.International journal of nanomedicine · 2024Article
- Intratumoral co-injection of NK cells and NKG2A-neutralizing monoclonal antibodies.EMBO molecular medicine · 2023Article
- Engineered tumor-specific T cells using immunostimulatory photothermal nanoparticles.Cytotherapy · 2023Article
- Review
- Multiplexed In Situ Spatial Protein Profiling in the Pursuit of Precision Immuno-Oncology for Patients with Breast Cancer.Cancers · 2022Review
- The Thermal Dose of Photothermal Therapy Generates Differential Immunogenicity in Human Neuroblastoma Cells.Cancers · 2022Article
- Review
- Diversifying the platinum-based chemotherapy toolkit for immunogenic cancer cell death.Oncotarget · 2020Article
- Primary and metastatic breast tumors cross-talk to influence immunotherapy responses.Oncoimmunology · 2020Article
- Review
Corrections and comments
- Comment on
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Whether cell death caused by T lymphocytes and natural killer (NK) cells would be immunogenic
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.